Proteome Sciences (LON:PRM) Shares Up 45.5% – Still a Buy?

Proteome Sciences plc (LON:PRM) shares were up 45.5% on Wednesday . The company traded as high as GBX 2.50 and last traded at GBX 2.40. Approximately 1,057,249 shares were traded during mid-day trading, an increase of 338% from the average daily volume of 241,283 shares. The stock had previously closed at GBX 1.65.

Proteome Sciences Trading Down 14.5%

The business has a 50 day simple moving average of GBX 1.90 and a 200-day simple moving average of GBX 2.67. The company has a debt-to-equity ratio of -258.66, a quick ratio of 0.37 and a current ratio of 0.20. The stock has a market capitalization of £7.07 million, a P/E ratio of -2.12 and a beta of 0.07.

Proteome Sciences (LON:PRM) last posted its quarterly earnings data on Thursday, September 25th. The company reported GBX (0.73) EPS for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.